Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer-Mature Results of the ARTSCAN III Trial

Gebre-Medhin, Maria LU ; Adrian, Gabriel LU orcid ; Engström, Per LU ; Cange, Hedda Haugen ; Hammarstedt-Nordenvall, Lalle ; Reizenstein, Johan ; Brun, Eva LU ; Nyman, Jan ; Abel, Edvard and Friesland, Signe , et al. (2025) In International Journal of Radiation Oncology, Biology, Physics
Abstract

PURPOSE: The study investigated curative radiation therapy (RT) plus cisplatin versus RT plus cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

METHODS AND MATERIALS: This was a Swedish multicenter randomized phase 3 study. Included patients were randomized 1:1. Patients with T3-T4 tumors underwent a second randomization 1:1 between a final RT dose of 68.0 and 73.1 Gy to the primary tumor. Cisplatin dosage was 40 mg/m2/wk during RT. Cetuximab was administered with a loading dose of 400 mg/m2 1 week before start of RT, followed by weekly doses of 250 mg/m2 during RT. Primary endpoint was overall survival (OS), evaluated by adjusted Cox regression analysis. Secondary endpoints were... (More)

PURPOSE: The study investigated curative radiation therapy (RT) plus cisplatin versus RT plus cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).

METHODS AND MATERIALS: This was a Swedish multicenter randomized phase 3 study. Included patients were randomized 1:1. Patients with T3-T4 tumors underwent a second randomization 1:1 between a final RT dose of 68.0 and 73.1 Gy to the primary tumor. Cisplatin dosage was 40 mg/m2/wk during RT. Cetuximab was administered with a loading dose of 400 mg/m2 1 week before start of RT, followed by weekly doses of 250 mg/m2 during RT. Primary endpoint was overall survival (OS), evaluated by adjusted Cox regression analysis. Secondary endpoints were locoregional control, pattern of failure, morbidity, quality of life (QL), and comparisons between dose-escalated RT and standard-dose RT in T3-T4 tumors.

RESULTS: Following an unplanned interim analysis, patient inclusion was prematurely closed. The intention-to-treat population included 291 patients, 76% of whom had p16-positive oropharyngeal cancer. Median follow-up was 7.5 years for OS and 5.3 years for treatment efficacy. Five-year OS was 82% (95% confidence interval [CI], 76-89) in the RT plus cisplatin group compared with 71% (95% CI, 64-79) in the RT plus cetuximab group (log-rank P = .019). Adjusted hazard ratios for OS, locoregional failure, and distant failure were 1.66 (95% CI, 1.08-2.56; P = .021), 2.24 (95% CI, 1.25-4.02; P = .007), and 1.44 (95% CI, 0.67-3.09; P = .34), respectively, for patients treated with concomitant cetuximab versus cisplatin. Although potentially affected by the early termination of patient inclusion, no improvement in local control was found in patients with T3-T4 tumors receiving RT dose escalation (adjusted HR, 0.63; 95% CI, 0.30-1.34; P = .23). Late morbidity and QL were similar between the treatment groups.

CONCLUSIONS: The study showed inferior treatment outcomes for cetuximab compared with cisplatin concurrent with RT. Cisplatin remains standard concomitant treatment for locoregionally advanced HNSCC.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
International Journal of Radiation Oncology, Biology, Physics
publisher
Elsevier
external identifiers
  • pmid:40543675
ISSN
0360-3016
DOI
10.1016/j.ijrobp.2025.05.086
language
English
LU publication?
yes
additional info
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
id
d51831b8-1fdf-452f-a345-5ea8c3df0431
date added to LUP
2025-08-14 10:19:15
date last changed
2025-08-14 11:34:41
@article{d51831b8-1fdf-452f-a345-5ea8c3df0431,
  abstract     = {{<p>PURPOSE: The study investigated curative radiation therapy (RT) plus cisplatin versus RT plus cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).</p><p>METHODS AND MATERIALS: This was a Swedish multicenter randomized phase 3 study. Included patients were randomized 1:1. Patients with T3-T4 tumors underwent a second randomization 1:1 between a final RT dose of 68.0 and 73.1 Gy to the primary tumor. Cisplatin dosage was 40 mg/m2/wk during RT. Cetuximab was administered with a loading dose of 400 mg/m2 1 week before start of RT, followed by weekly doses of 250 mg/m2 during RT. Primary endpoint was overall survival (OS), evaluated by adjusted Cox regression analysis. Secondary endpoints were locoregional control, pattern of failure, morbidity, quality of life (QL), and comparisons between dose-escalated RT and standard-dose RT in T3-T4 tumors.</p><p>RESULTS: Following an unplanned interim analysis, patient inclusion was prematurely closed. The intention-to-treat population included 291 patients, 76% of whom had p16-positive oropharyngeal cancer. Median follow-up was 7.5 years for OS and 5.3 years for treatment efficacy. Five-year OS was 82% (95% confidence interval [CI], 76-89) in the RT plus cisplatin group compared with 71% (95% CI, 64-79) in the RT plus cetuximab group (log-rank P = .019). Adjusted hazard ratios for OS, locoregional failure, and distant failure were 1.66 (95% CI, 1.08-2.56; P = .021), 2.24 (95% CI, 1.25-4.02; P = .007), and 1.44 (95% CI, 0.67-3.09; P = .34), respectively, for patients treated with concomitant cetuximab versus cisplatin. Although potentially affected by the early termination of patient inclusion, no improvement in local control was found in patients with T3-T4 tumors receiving RT dose escalation (adjusted HR, 0.63; 95% CI, 0.30-1.34; P = .23). Late morbidity and QL were similar between the treatment groups.</p><p>CONCLUSIONS: The study showed inferior treatment outcomes for cetuximab compared with cisplatin concurrent with RT. Cisplatin remains standard concomitant treatment for locoregionally advanced HNSCC.</p>}},
  author       = {{Gebre-Medhin, Maria and Adrian, Gabriel and Engström, Per and Cange, Hedda Haugen and Hammarstedt-Nordenvall, Lalle and Reizenstein, Johan and Brun, Eva and Nyman, Jan and Abel, Edvard and Friesland, Signe and Sjödin, Helena and Söderkvist, Karin and Thomasson, Marcus and Zackrisson, Björn and Nilsson, Per}},
  issn         = {{0360-3016}},
  language     = {{eng}},
  month        = {{06}},
  publisher    = {{Elsevier}},
  series       = {{International Journal of Radiation Oncology, Biology, Physics}},
  title        = {{Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer-Mature Results of the ARTSCAN III Trial}},
  url          = {{http://dx.doi.org/10.1016/j.ijrobp.2025.05.086}},
  doi          = {{10.1016/j.ijrobp.2025.05.086}},
  year         = {{2025}},
}